Evidence map›Paper›PMID 39220525›Full record

ArticleACS omega2024

Evaluation of ABD-Linked RM26 Conjugates for GRPR-Targeted Drug Delivery.

Ábel Nagy, Ayman Abouzayed, Panagiotis Kanellopoulos, Fredrika Landmark, Ekaterina Bezverkhniaia, Vladimir Tolmachev, Anna Orlova, Amelie Eriksson Karlström

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ábel NagyDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Center, 106 91 Stockholm, Sweden.
Ayman AbouzayedDepartment of Medicinal Chemistry, Uppsala University, 752 37 Uppsala, Sweden.
Panagiotis KanellopoulosDepartment of Medicinal Chemistry, Uppsala University, 752 37 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-0617-3936
Fredrika LandmarkDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Center, 106 91 Stockholm, Sweden.
Ekaterina BezverkhniaiaDepartment of Medicinal Chemistry, Uppsala University, 752 37 Uppsala, Sweden.
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 752 37 Uppsala, Sweden.ORCID https://orcid.org/0000-0001-6120-2683
Amelie Eriksson KarlströmDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Center, 106 91 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-0695-5188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting the gastrin-releasing peptide receptor (GRPR) with the bombesin analogue RM26, a 9 aa peptide, has been a promising strategy for cancer theranostics, with recent success in radionuclide imaging of prostate cancer. However, therapeutic application of the short peptide RM26 would require a longer half-life to prevent fast clearance from the circulation. Conjugation to an albumin-binding domain (ABD) is a viable strategy to extend the

Identifiers

PMID39220525
PMCPMC11359615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.